Literature DB >> 9394193

Immunological approaches for the control of fasciolosis.

T W Spithill1, D Piedrafita, P M Smooker.   

Abstract

The immunological relationship between liver flukes and their mammalian hosts is being unravelled by in vivo and in vitro studies. Vaccine studies in cattle and sheep with purified antigens (fatty acid binding protein, FABP; glutathione S-transferase, GST; cathepsin L, CatL; hemoglobin) have shown that high reductions in worm burdens (31-72%) and egg production (69-98%) can be achieved, raising the realistic possibility that immunological control of Fasciola infection is a commercially achievable goal. Combination vaccines may also be feasible since a cocktail of CatL and hemoglobin elicits a significant 72% protection in cattle. Analysis of immune responses to Fasciola during infection in ruminants suggests that chronic infection correlates with a type 2 helper T cell response, implying that type 1 helper T cell responses are down-regulated in fasciolosis. Recent results studying the resistance of Indonesian Thin Tail (ITT) sheep to F. gigantica have shown that this breed exhibits high innate (or rapidly acquired) resistance to infection and acquires a higher level of resistance after a primary challenge. Initial studies suggest that the resistance of ITT sheep to F. gigantica may be determined by a major gene. Merino sheep also acquire resistance to F. gigantica. In contrast, ITT and Merino sheep do not exhibit resistance to F. hepatica. These results suggest that there are fundamental differences between these two species of Fasciola in the biology of their interaction with the sheep immune system. In vitro studies on immune mechanisms of killing of juvenile fluke have shown that juvenile larvae of F. hepatica are susceptible to antibody-dependent killing by activated rat macrophages in vitro which is mediated by nitric oxide. Future studies on the immune effector mechanisms expressed by resistant sheep which control infection by F. gigantica will lead to new knowledge which may allow the design of more effective vaccines for fasciolosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9394193     DOI: 10.1016/s0020-7519(97)00120-3

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN: 0020-7519            Impact factor:   3.981


  6 in total

1.  Comparison of modulation of sheep, mouse and buffalo lymphocyte responses by Fasciola hepatica and Fasciola gigantica excretory-secretory products.

Authors:  W Zhang; E Moreau; F Peigné; W Huang; A Chauvin
Journal:  Parasitol Res       Date:  2005-02-12       Impact factor: 2.289

2.  Peritoneal lavage cells of Indonesian thin-tail sheep mediate antibody-dependent superoxide radical cytotoxicity in vitro against newly excysted juvenile Fasciola gigantica but not juvenile Fasciola hepatica.

Authors:  David Piedrafita; Endah Estuningsih; Jill Pleasance; Rhoda Prowse; Herman W Raadsma; Els N T Meeusen; Terry W Spithill
Journal:  Infect Immun       Date:  2007-01-08       Impact factor: 3.441

3.  Characterization of specific and cross-reacting antigens of Fasciola gigantica by immunoblotting.

Authors:  S Yokananth; S Ghosh; S C Gupta; M G Suresh; D Saravanan
Journal:  Parasitol Res       Date:  2005-06-11       Impact factor: 2.289

4.  Early detection of Fasciola gigantica infection in buffaloes by enzyme-linked immunosorbent assay and dot enzyme-linked immunosorbent assay.

Authors:  Niranjan Kumar; S Ghosh; S C Gupta
Journal:  Parasitol Res       Date:  2008-06       Impact factor: 2.289

5.  Detection of Fasciola gigantica infection in buffaloes by enzyme-linked immunosorbent assay.

Authors:  Niranjan Kumar; S Ghosh; S C Gupta
Journal:  Parasitol Res       Date:  2008-09-10       Impact factor: 2.289

6.  Discovery and validation of serum biomarkers expressed over the first twelve weeks of Fasciola hepatica infection in sheep.

Authors:  M-C Rioux; C Carmona; D Acosta; B Ward; M Ndao; B F Gibbs; H P Bennett; T W Spithill
Journal:  Int J Parasitol       Date:  2007-08-14       Impact factor: 3.981

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.